Caprock Group LLC Purchases New Shares in West Pharmaceutical Services, Inc. $WST

Caprock Group LLC purchased a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,965 shares of the medical instruments supplier’s stock, valued at approximately $1,473,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC acquired a new position in shares of West Pharmaceutical Services during the second quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC raised its position in West Pharmaceutical Services by 193.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 95 shares during the last quarter. SJS Investment Consulting Inc. lifted its holdings in West Pharmaceutical Services by 1,842.9% during the 3rd quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 129 shares in the last quarter. CVA Family Office LLC boosted its position in West Pharmaceutical Services by 573.3% in the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock valued at $44,000 after buying an additional 172 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in West Pharmaceutical Services in the 3rd quarter valued at $47,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Up 2.6%

Shares of NYSE WST opened at $249.99 on Friday. West Pharmaceutical Services, Inc. has a 52-week low of $187.43 and a 52-week high of $322.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.18 and a current ratio of 3.02. The stock has a market cap of $17.98 billion, a P/E ratio of 36.82, a P/E/G ratio of 3.31 and a beta of 1.18. The firm has a 50 day moving average price of $260.95 and a 200 day moving average price of $261.61.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.21. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The company had revenue of $805.00 million for the quarter, compared to analysts’ expectations of $795.70 million. During the same period last year, the firm posted $1.82 earnings per share. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Analysts expect that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 4th. Shareholders of record on Wednesday, January 28th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Wednesday, January 28th. West Pharmaceutical Services’s dividend payout ratio is 13.04%.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Beat-and-guide: WST reported Q4 EPS of $2.04 vs. $1.83 consensus and revenue of $805M, and issued FY‑2026 EPS guidance of $7.85–$8.20 with revenue ~$3.2–3.3B — the core reason investors pushed the stock higher. West Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Strong demand for drug components: Reuters highlights management’s forecast for 2026 profit above estimates driven by robust demand for HVP components (syringes, cartridges), supporting margin and cash‑flow outlook. West Pharma forecasts 2026 profit above estimates on strong demand for drug components
• Positive Sentiment: Proprietary product progress and outlook: Company commentary and analyst notes emphasize SmartDose and HVP-led growth, with management signaling SmartDose sale activity by mid‑2026 — a potential revenue/margin driver. WST’s Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up
• Positive Sentiment: Analyst support: TD Cowen reiterated a Buy and kept a $350 price target, citing non‑GLP‑1 growth, margin expansion and regulatory tailwinds — reinforcing investor confidence. Buy Rating on West
• Positive Sentiment: Market reaction coverage: Multiple outlets (Yahoo, Seeking Alpha, TipRanks) note stock strength following results and outlook, reflecting broad positive market reception. West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook
• Neutral Sentiment: Guidance detail and call transcript: The full earnings call transcript and slide deck provide execution details and cadence for HVP and SmartDose commercialization — useful for modeling but not new directional news. West Pharmaceutical Services Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Peer/value comparison: A Zacks piece compares Cooper (COO) and WST for value seekers — useful for allocation decisions but not directly driving WST’s move. COO vs. WST: Which Stock Is the Better Value Option?
• Neutral Sentiment: Macro market commentary: Coverage noting WST’s role in broader indices/futures is descriptive — relevant for positioning but secondary to fundamentals. Is West Pharmaceutical Services (NYSE:WST) a Pillar In S&P 500 Futures Performance
• Negative Sentiment: Relative underperformance note: MarketWatch flags that WST has underperformed some competitors recently despite daily gains — a reminder of sector competition and potential valuation scrutiny. West Pharmaceutical Services Inc. stock underperforms despite daily gains

Analyst Upgrades and Downgrades

WST has been the topic of several research reports. UBS Group reaffirmed a “buy” rating and set a $340.00 price target on shares of West Pharmaceutical Services in a research note on Friday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a research report on Friday. Evercore reduced their target price on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 3rd. Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Buy” and an average price target of $314.56.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.